Kornimate/medical-research-clean huggingface dataset:
evaluation of an acceptance and commitment therapy-based narrative intervention for individuals taking antidepressants

Conditions: Depressive Symptoms

Summary: this study aims to compare the efficacy of lifestories on depression symptomatology compared to antidepressant treatment alone, in addition to examining the effect of the intervention on health-related quality of life. participants will be randomly assigned to either an online act-based narrative intervention (lifestories) or the waitlist control condition (antidepressant treatment alone). it is hypothesized that participants who receive the lifestories will result in decreased depression and increased quality of life, general functioning and decreased psychological inflexibility compared to the waitlist group.

the purpose of this study is to test the efficacy of an online, self-guided act-based narrative intervention for adults currently taking antidepressant medication. to test the effects of lifestories on depression severity, quality of life, general functioning and psychological inflexibility, the investigators will conduct a randomized controlled trial with two conditions (lifestories and waitlist control) using a sample of 90 adults currently taking antidepressant medication. interested individuals will complete a screening survey to determine eligibility. after being informed about the study and potential risks, eligible participants who provide informed consent will be asked to complete a baseline survey. participants will then be randomized to lifestories or a waitlist control conditions, each lasting 4 weeks. those in the waitlist group will be asked to not use other self-help websites or books for four weeks, after which they will be given weekly access to lifestories modules. participants in both groups will be asked to complete a midtreatment survey 2 weeks after baseline, and a posttreatment survey 4 weeks after baseline (i.e. after completing the 4-week video intervention for those in the active condition).

Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. currently residing in the united states 3. currently taking antidepressant medication prescribed by a primary care provider (pcp) 4. meets criteria for at least moderate depression on the 9-item patient health questionnaire 5. fluent in english 6. reliable access to an internet browser, and internet speed that is sufficient for streaming online videos exclusion criteria: 1. change in medication regimen in past 6 weeks 2. presently seeing a mental health specialist (e.g. psychologist, psychiatrist, counselor, social worker)

Keywords: act narrative intervention story-telling intervention depression antidepressant
feasibility neurocognitive outcome after transplant

Conditions: Stem Cell Transplantation; Pediatric Cancer; Acute Lymphoblastic Leukemia

Summary: this pilot study will primarily be evaluated by feasibility and adherence to an ipad-based neurocognitive intervention program. it will secondarily be evaluated by performance on the neurocognitive testing post-transplant and change in performance in subsequent years.


Eligibility criteria:
inclusion criteria: * all patients must have a histologic or cytological diagnosis of all treated with stem cell transplantation. there are no restrictions on prior therapy. * patients must be between the ages of 6 years and 21 years of age (inclusive), but there will be no discrimination based on gender, race, creed, or ethnic background. the age limits are set at 6 years of age in order to ensure that patients will be able to participate in these specific cognitive rehabilitation tasks. ecog/kps will not be employed. * patient and/or parents/guardians as appropriate must sign an informed consent, be mentally responsible, able to understand and willing to sign a written informed consent. exclusion criteria: * subjects with significant concurrent medical complications that in the judgment of the principal investigator(s) could affect the patient's ability to complete the planned trial. there are no therapy restrictions or restrictions regarding the use of other investigational agents. * pregnant patients will be excluded.
a trial of neoadjuvant ts-1 and cisplatin for type 4 and large type 3 gastric cancer

Conditions: Gastric Neoplasm

Summary: the aim of this study is to evaluate survival benefit of ts-1 plus cisplatin as a neoadjuvant chemotherapy in gastric cancer patient with resectable type 4 (linitis plastica type) and large type 3 tumor in comparison with surgery alone.

a randomized phase iii study is going to started in japan to compare ts-1 plus cisplatin as a neoadjuvant chemotherapy with surgery alone in patient with type 4 and large type 3 gastric cancer.a total of 300 patients will be accrued for this study from 35 institutions within five years. the primary endpoint is overall survival. the secondary endpoints are progression free survival (pfs), response rate, proportion of protocol achievement, proportion of curative resection, and adverse events.

Eligibility criteria:
inclusion criteria: 1. histologically proven adenocarcinoma of stomach 2. borrmann type 4 or large (\>=8 cm) type 3 3. no evidence of distant metastasis including liver(m0) 4. no evidence of para-aortic and/or retropancreatic lymph node metastasis(n0-2) 5. no peritoneal metastasis and negative peritoneal lavage cytology (pls) with laparoscopic confirmation 6. no involvement of the esophagus with \> 3cm 7. an age of 20-75 years 8. an eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1 9. no prior chemotherapy, radiotherapy for any malignancy 10. no prior surgery for gastric cancer except for endoscopic membrane resection (emr) 11. no breeding from primary tumor or gastrointestinal stenosis 12. sufficient oral intake 13. adequate organ function 14. written informed consent exclusion criteria: 1. synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 2. pregnant or breast-feeding women 3. severe mental disease 4. systemic administration of corticosteroids, flucytosine, phenytoin or warfarin 5. other severe complications such as paralytic ileus, intestinal pneumonitis, pulmonary fibrosis, or ischemic heart disease 6. myocardial infarction within six disease-free months

Keywords: neoadjuvant therapy stomach neoplasms cisplatin s-1(combination)
effectiveness of intracytoplasmic sperm injection and laser assisted hatching on in vitro fertilization outcomes of patients with different causes of infertility

Conditions: Infertility

Summary: to determine the association of factors affecting the clinical pregnancy and live birth rates in patients undergoing in vitro fertilization (ivf) who received intracytoplasmic sperm injection (icsi) and/or laser assisted hatching (lah) or neither. after applying the inclusion and exclusion criteria, a total of 400 women who underwent ivf between january 2007 and december 2010 were included in the analysis. patients were divided into 4 groups; 1) those that did not receive icsi or lah, 2) those that received icsi only, 3) those that received lah only, and 4) those that received both icsi and lah. univariate and multivariate analyses were performed.


Eligibility criteria:
inclusion criteria: * the present study was a retrospective review of the outcomes of women who underwent ivf with or without intracytoplasmic sperm injection (icsi) at the far eastern memorial hospital, taipei, taiwan, between january 2007 and december 2010. exclusion criteria: * cases in which estradiol levels exceeded 50 pg/ml on the second day of the menstrual cycle were excluded. * female minors or disabled persons.
11c topotecan pet imaging

Conditions: Lung Cancer; Metastatic Cancer; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: diagnostic procedures, such as positron emission tomography (pet scan) using 11c topotecan, may help doctors predict a patient's response to treatment and help plan the best treatment. purpose: this phase i/ii trial is studying how well a pet scan using 11c topotecan predicts response to treatment in patients with brain metastases due to ovarian, small cell lung, or other cancer.

objectives: primary * determine if tumor uptake of \^11c topotecan occurs quickly enough and at sufficient concentration to be measured immediately following infusion in patients with brain metastases secondary to ovarian cancer, small cell lung cancer, or other cancers. * determine, preliminarily, if \^11c imaging has potential to be an early predictor of response to topotecan therapy in these patients. secondary * determine the whole-body biodistribution of \^11c topotecan in these patients. outline: * phase i: patients receive \^11c topotecan iv over 10 minutes followed immediately by a 1-2 hour positron emission tomography (pet) scan. within 4 weeks after initial imaging, patients also undergo a ct scan. * phase ii: patients receive \^11c topotecan and undergo imaging as in phase i. patients also receive fludeoxyglucose f 18 iv and, 1 hour later, undergo a pet scan. projected accrual: a total of 10 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed ovarian cancer, small cell lung cancer, or other cancers * metastatic brain disease * eligible for topotecan therapy * measurable disease by ct scan and/or mri patient characteristics: performance status * ecog 0-2 life expectancy * more than 3 months hematopoietic * wbc ≥ 3,000/mm\^3 * platelet count ≥ 100,000/mm\^3 hepatic * not specified renal * creatinine clearance ≥ 50 ml/min other * not pregnant or nursing * adequate end-organ function * able to tolerate lying on a radiology table for ≥ 1 hour * no serious medical or psychiatric illness that would preclude study compliance or giving informed consent prior concurrent therapy: not specified

Keywords: stage iv ovarian epithelial cancer stage iv ovarian germ cell tumor extensive stage small cell lung cancer recurrent small cell lung cancer unspecified adult solid tumor, protocol specific recurrent ovarian epithelial cancer recurrent ovarian germ cell tumor tumors metastatic to brain
pharmacokinetics, pharmacodinamic and safety of testosterone gel 1%

Conditions: Post-menopausal Period

Summary: this is a phase i, open-label, parallel trial to evaluate pharmacokinetics, pharmacodynamics and safety of testosterone gel 1% for topic usage in post-menopausal women, for 28 days

this is a phase i, open-label, parallel trial to evaluate pharmacokinetics, pharmacodynamics and safety of testosterone gel 1% for topic usage in post-menopausal women, study participants will receive investigational product for 28 consecutive days, once daily, as per the following allocation: 2.2 mg, 4.4 mg. 8.8 mg or placebo.

Eligibility criteria:
inclusion criteria: * female subjects aged ≥ 42 years and ≤ 65 years, in post-menopausal period for at least 1 year and with active sexual life; * serum testosterone levels \< 33 ng/ml; * follicle-stimulating hormone (fsh) levels \> 22 mu/ml; * absence of other significant diseases which, at the physician's discretion, could impact subject's participation in the trial, according to protocol requirements, and study evaluations: medical history, blood pressure and heart rate measurements, physical examination and complimentary laboratory tests; * ability to understand the nature and objective of the trial, including risks and adverse events, which shall be confirmed by informed consent form signature. exclusion criteria: * screening laboratory tests results presenting clinically relevant deviations that, at the investigator discretion, prevent the subject to participate in the trial due to possible risks; * drugs addiction, including alcohol; * treatment with any drugs known to have a well-established toxic potential to major organs, within 3 months before the trial, ; * participation in any other experimental research or administration of any experimental drug within six months before the initiation of this trial; * pregnancy, labor or miscarriage in the last 12 weeks before the antecipated date of the study treatment start; * any conditions, according to investigator's best judgement, that prevents the subject to participate in the trial.
an observational study of environmental and socioeconomic factors in opioid recovery

Conditions: Opioid-use Disorder; Opioid-related Disorders

Summary: the recover study will examine clinical, environmental and socioeconomic factors in recovery from opioid use disorder (oud) over a 24-month period following exit from a phase iii clinical program for a buprenorphine extended-release injection (rbp-6000). the study population will consist of participants from studies nct02357901 (rb-us-13-0001) and nct02510014 (rb-us-13-0003). the recover study will characterize oud subjects' recovery process as they transition from the controlled clinical trial environment to the real world setting.


Eligibility criteria:
inclusion criteria: * subjects who received at least one injection in rbp-6000 or placebo in the phase iii clinical program which includes study protocols nct02357901 (rb-us-13-0001) and nct02510014 (rb-us-13-0003) and either withdrew from or completed these studies. * ability to comply with study protocol requirements for data collection and provide informed consent.

Keywords: opioid recovery recovery opioid-related disorders substance-related disorders heroin dependence opioid dependence addiction buprenorphine opiate substitution treatment analgesics opioid narcotics patient outcome assessment patient-centered care cost of illness employment health-related quality-of-life family relations lifestyle citizenship
the role of a private hospital in hong kong amid covid-19 pandemic

Conditions: COVID

Summary: hong kong public healthcare system is facing tremendous pressure under the covid-19 pandemic. as the virus spread in hong kong, hong kong sanatorium \& hospital (hksh) is one of the first private hospitals which immediately provide reliable and rapid covid-19 test -- reverse transcription polymerase chain reaction (rt-pcr). early provision of the rt-pcr screening test for covid-19 not only facilitates identification of covid-19 but also contains the spread of the virus in the community and frontline medical staff. since description of role of private hospital in hong kong amid covid-19 pandemic is lacking, this study will describe covid-19 screening algorithm and methodology. a retrospective analysis on clinical characteristics, laboratory findings as well as outcome of patients who underwent covid-19 test in hksh is also performed.


Eligibility criteria:
inclusion criteria: * subjects who underwent covid-19 test in hksh during the study period exclusion criteria: -
scri tissue testing registry

Conditions: Melanoma; Myelodysplastic Syndrome; Multiple Myeloma; Lymphoma

Summary: sarah cannon research institute (scri) is committed to improvement and excellence in clinical research and correlative science. to this end, the scri oncology research consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. these markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

sarah cannon research institute (scri) is committed to improvement and excellence in clinical research and correlative science. to this end, the scri oncology research consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. these markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions. this study will consist of a registry of patients who have agreed to allow their tissue sample(s) (even those taken prior to their participation in an scri-sponsored trial) to be used by the scri oncology research consortium at some point in the future for testing and analysis of expression analysis and/or analysis of tumor markers. the registry will be contained in an electronic database, and will be sorted by disease indication. (note: patients will not be asked to return at a future date and have tissue samples collected; rather, scri will have the authorization to obtain pre-existing samples).

Eligibility criteria:
inclusion criteria: * patients must be \>= 18 years of age. * patients must be able to provide written informed consent. exclusion criteria: * not applicable

Keywords: tissue registry tissue collection unknown primary breast lung gastrointestinal bone marrow transplant chronic lymphocytic leukemia central nervous system head and neck melanoma myelodysplastic syndrome multiple myeloma lymphoma gynecologic genitourinary refractory malignancy
pain control in renal colic

Conditions: Renal Colic

Summary: renal colic is very common in emergency department patients. our aim of this study is which combination of drug is more effective in renal colic.


Eligibility criteria:
inclusion criteria: * adult, clinical suspicion of renal colic exclusion criteria: * under 15 * do not consent * contraindication of morphine, ketorolac, or buscopan * previously pain controlled

Keywords: renal colic
triple therapy of pars plana vitrectomy and grid/focal laser for diabetic macular edema (dme)

Conditions: Diabetic Retinopathy; Macular Edema

Summary: this study is designed to report 3-year result of triple therapy of vitrectomy, intravitreal triamcinolone and macular laser photocoagulation for intractable diabetic macular edema. previously author reported 1-year result(am j ophthalmol. 2007 dec;144(6):878-885. epub 2007 oct 15.).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of diabetes mellitus * intractable diffuse dme (diffuse dme which did not respond to or recurred after the previous ivta and/or macular focal laser photocoagulation) * central subfield macular thickness (cst) greater than 250μm exclusion criteria: * presence of vitreomacular traction * a prior history of treatment for the dme within 3 months or vitreoretinal surgery

Keywords: diabetic macular edema combination therapy for dme dme
retrospective study of brachytherapy

Conditions: Brachytherapy; Uterine Cervical Neoplasms; Uterine Neoplasms; Vulvar Cancer; Vaginal Cancer; Ovarian Neoplasms; Gynecologic Neoplasm

Summary: brachytherapy for gynecological cancers will be studied retrospectively.


Eligibility criteria:
inclusion criteria: * 18 - 80 female * underwent brachytherapy * with gynecological cancer exclusion criteria: * refusal to enter this trial

Keywords: brachytherapy cervical cancer endometrial cancer vaginal cancer vulvar cancer image guided 3d print
radical retropubic prostatectomy versus conventional external beam radiotherapy for clinically localized prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to evaluate the effectiveness of the two most established primary treatments for patients with clinically localized prostate cancer: radical retropubic prostatectomy, and external-beam radiotherapy. the primary aim is assessing biochemical disease-free survival, overall survival, and prostate cancer-specific survival. as secondary objectives quality of life impact of treatments' side effects will be also assessed.

eligible patients had clinically localized (clinical tnm classification t1 or t2), biopsy-proven adenocarcinoma of the prostate and were randomly treated with rrp or ebrt. exclusion criteria included prior treatment for prostate cancer, the presence of metastatic disease on imaging studies, the receipt of neoadjuvant androgen ablation before registration, and an inability to read or understand italian language. the institutional review boards of every participating centre approved the study design. every patient enrolled signed an informed-consent form approved by the institutional review boards. clinical information collected from the medical record included pre-treatment serum prostate-specific antigen (psa) level, clinical t classification, and biopsy gleason score. follow-up assessments were completed before treatment and every 3 months after treatment. subjects who sought primary treatment elsewhere or did not return follow-up questionnaires beyond the initial assessment were excluded from this analysis.

Eligibility criteria:
inclusion criteria: * age 75 years or younger * diagnosis of prostate cancer, as verified by cytologic or histologic examination the tumor is well differentiated to moderately well differentiated * untreated, clinically localized prostate cancer, with a tumor stage of t1, or t2 * prostate specific antigen (psa) level of ≤10 ng/ml * bone scan with no abnormalities * health status that would permit radical prostatectomy * life expectancy of more than 10 years. exclusion criteria: * psa \>10 ng/ml * bone scan consistent with metastatic disease * other evidence that cancer of the prostate is not clinically localized * life expectancy less than 10 years * serum creatinine greater than 3 mg/dl * myocardial infarction within last 6 months * unstable angina class iii or iv * severe pulmonary disease * liver failure * severe dementia * debilitating illness malignancies, except for nonmelanomatous skin cancer, in the last 5 years.

Keywords: clinically localized prostate cancer radical retropubic prostatectomy external beam radiotherapy efficacy quality of life adverse events
diaphragm atrophy and dysfunction in mechanical ventilation

Conditions: Diaphragm Issues; Mechanical Ventilation Complication; Respiratory Failure; Intensive Care (ICU) Myopathy

Summary: the gold standard of twitch transdiaphragmatic pressure recordings would ultimately clear the fog around the rate of development of ventilator induced diaphragm dysfunction (vidd) in mechanically ventilated patients over time. through measurements made even after mechanical ventilation (mv) it could be clarified to what extent patients recover from vidd. paired with cortical stimulation and electromyographic recordings of diaphragm muscle potentials, it could be explored to what extent decreased diaphragm excitability due to long term mv contributes to vidd on the level of motor cortex. against that background the present project aims at determining the rate of decline in diaphragm function, strength and control in patients undergoing mv (including measurements after extubation).

evidence both from animal and human studies support the development of ventilator induced diaphragm dysfunction (vidd) from as early as 24 hours of mechanical ventilation (mv) in the intensive care unit (icu). however, while the concept of vidd seems to be proven now, several questions remain unanswered regarding its actual rate of development and (potentially) recovery after mv. the gold standard of twitch transdiaphragmatic pressure recordings would ultimately clear the fog around the rate of development of vidd over time. through measurements made even after mv it could be clarified to what extent patients recover from vidd. paired with cortical stimulation and electromyographic recordings of diaphragm muscle potentials, it could be explored to what extent decreased diaphragm excitability due to long term mv contributes to vidd on the level of motor cortex. against that background the present project aims at determining the rate of decline in diaphragm function, strength and control in patients undergoing mv (including measurements after extubation).

Eligibility criteria:
inclusion criteria: * initiation of invasive mechanical ventilation in the intensive care unit within 48 hours. * expected duration of invasive mechanical ventilation of at least 5 days. exclusion criteria: * body-mass-index (bmi) \>40 * expected absence of active participation of the patient in study-related measurements after extubation * alcohol or drug abuse * non mri compatible implant in the body * slipped disc * epilepsy * patients in an interdependence or with an employment contract with the principal investigator, co-pi or his deputy.